Discovery of EGFR kinase’s T790M variant inhibitors through molecular dynamics simulations, PCA-based dimension reduction, and hierarchical clustering

被引:0
|
作者
Rajneet Kaur Bijral
Inderpal Singh
Jatinder Manhas
Vinod Sharma
机构
[1] University of Jammu,Department of Computer Science and IT
[2] Bioinfores,Department of Computer Science and IT, Bhaderwah Campus
[3] University of Jammu,undefined
来源
Structural Chemistry | 2022年 / 33卷
关键词
EGFR kinase; T790M mutation; Resistance; Simulation; PCA; Clustering; Virtual screening;
D O I
暂无
中图分类号
学科分类号
摘要
Deregulation of epidermal growth factor receptors is one of the major causes of lung cancers, and its kinase has been targeted in associated therapy. Often, mutations causing resistance to therapy have been observed in the patients leading to their poor survival. Even after designing the mutant-specific irreversible inhibitors, the issue to deal with resistance to therapy still remains. Molecular dynamics simulations of biological macromolecules such as proteins offer a greater understanding of biological mechanisms at an atomistic detail. In the present study, principal component analysis-multiple dimension reduction technique and hierarchical clustering was employed in EGFR kinase’s T790M mutant form’s simulated trajectory to select five diverse conformers for ensemble based virtual screening of 52,000 drug-like molecules from Maybridge library. Further, 50 ns molecular dynamics simulations was conducted on the complexes of top 8 molecules with mutated kinase to validate the binding consistency of these molecules. The strong binding energies and stable dynamics of the simulated complex suggest these molecules to be valuable for drug discovery.
引用
收藏
页码:1957 / 1964
页数:7
相关论文
共 43 条
  • [31] Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
    Suriya, Utid
    Mahalapbutr, Panupong
    Wimonsong, Watchara
    Yotphan, Sirilata
    Choowongkomon, Kiattawee
    Rungrotmongkol, Thanyada
    MOLECULES, 2022, 27 (24):
  • [32] EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
    Rangachari, Deepa
    To, Ciric
    Shpilsky, Jason E.
    VanderLaan, Paul A.
    Kobayashi, Susumu S.
    Mushajiang, Mierzhati
    Lau, Christie J.
    Paweletz, Cloud P.
    Oxnard, Geoffrey R.
    Janne, Pasi A.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 1995 - 2002
  • [33] Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors
    Zhou, Zhen
    Zhao, Yi
    Shen, Shengping
    Gu, Linping
    Niu, Xiaomin
    Xu, Yunhua
    Zhang, Tengfei
    Xiang, Jianxing
    Mao, Xinru
    Lu, Shun
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) : E157 - E159
  • [34] BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC)
    Patel, Harun M.
    Shaikh, Matin
    Ahmad, Iqrar
    Lokwani, Deepak
    Surana, Sanjay J.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (08): : 2838 - 2856
  • [35] Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment
    Wang, Cheng
    Wang, Xin
    Huang, Zhi
    Wang, Tianqi
    Nie, Yongwei
    Yang, Shengyong
    Xiang, Rong
    Fan, Yan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 237
  • [36] AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
    Choi, Geunho
    Kim, Daegeun
    Oh, Junehwan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Response to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients with de novo epidermal growth factor receptor (EGFR) T790M and S7681 resistance mutations.
    Kelly, Deirdre
    Prior, Lisa Mary
    Gleeson, Jack Patrick
    McSorley, Lynda M.
    Kearns, Rachel
    Brady, Claire
    Sui, Jane Sze Yin
    Dawod, Mohammed Adam Ibrahim
    Burke, Louise
    McCarthy, Julie
    McDermott, Ray
    McCaffrey, John
    Power, Derek Gerard
    O'Reilly, Seamus
    O'Mahony, Deirdre
    Finn, Stephen P.
    O'Brien, Cathal
    Bambury, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR (T790M/C797S) and VEGFR-2 in non-small cell lung cancer through in silico screening, ADMET, dynamics simulation, and DFT analysis
    Munna, Md. Masudur Rahman
    Tusar, Md. Touki Tahamid
    Shanta, Saima Sajnin
    Ahmed, Md. Hossain
    Ali, Md. Sarafat
    JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, 2024, 22 (03):
  • [39] Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity
    Akher, Farideh Badichi
    Farrokhzadeh, Abdolkarim
    Ravenscroft, Neil
    Kuttel, Michelle M.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2020, 124 (28): : 5813 - 5824
  • [40] New S- and N- alkyl functionalized bis-1,2,4-Triazolyl-based derivatives as potential dual EGFRWT and EGFR T790M inhibitors: Synthesis , anti-proliferative evaluation, molecular docking study and ADMET studies
    Ahmed, Abdelraheem M.
    Aboelez, Moustafa O.
    Ezelarab, Hend A. A.
    Khodairy, Ahmed
    Hassan, Abdelfattah
    User, Marium Abo
    Salah, Hanan
    JOURNAL OF MOLECULAR STRUCTURE, 2025, 1324